eIF4B Inhibitors are a class of compounds that target the eukaryotic initiation factor 4B (eIF4B), a critical component of the translation initiation machinery in eukaryotic cells. eIF4B plays a key role in facilitating the recruitment of ribosomes to messenger RNA (mRNA), a process that is essential for the synthesis of proteins. Specifically, eIF4B enhances the helicase activity of eIF4A, another initiation factor, which unwinds secondary structures in the 5' untranslated region (UTR) of mRNA. This unwinding is necessary for the small ribosomal subunit to scan the mRNA and locate the start codon, thereby initiating translation. Inhibitors of eIF4B disrupt this process, potentially leading to a reduction in global protein synthesis, as well as selective effects on the translation of specific mRNAs that are particularly dependent on eIF4B activity.
Research into eIF4B Inhibitors is valuable for understanding the regulation of translation, a fundamental process that controls gene expression at the post-transcriptional level. By inhibiting eIF4B, scientists can investigate the effects on mRNA translation, especially those mRNAs with complex secondary structures in their 5' UTRs, which are more reliant on eIF4B for efficient translation. This can provide insights into how cells control the synthesis of proteins in response to various stimuli and conditions, such as stress, nutrient availability, and signaling pathways. Additionally, eIF4B is known to interact with other components of the translation initiation complex, including eIF3 and the cap-binding protein eIF4E, so its inhibition may shed light on the broader network of interactions that regulate translation initiation. Understanding these interactions is crucial for unraveling the complexities of translational control and its impact on cellular function, growth, and adaptation. Researchers can use eIF4B Inhibitors as tools to dissect these processes, thereby contributing to a deeper knowledge of how cells regulate protein production in both normal and altered states.
Items 1 to 10 of 16 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $33.00 $102.00 | 87 | |
Salubrinal抑制eIF2α去磷酸化,延长磷酸化时间,从而减少翻译起始。 | ||||||
Guanabenz HCl | 23113-43-1 | sc-507500 | 100 mg | $241.00 | ||
瓜那本斯通过激活eIF2α磷酸酶PP1来减少eIF2α的磷酸化,从而允许翻译正常进行。 | ||||||
GSK 2606414 | 1337531-36-8 | sc-490182 sc-490182A | 5 mg 25 mg | $160.00 $561.00 | ||
GSK2606414抑制磷酸酶PERK的活性,后者会磷酸化eIF2α,从而降低eIF2α的磷酸化水平。 | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
顺铂通过造成DNA损伤、触发综合应激反应和eIF2α磷酸化,间接影响eIF2α。 | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin诱导ER应激,激活PERK并导致eIF2α磷酸化,从而抑制蛋白质合成。 | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
依托泊苷导致DNA损伤,从而可能引发细胞应激反应,从RNAi途径转移细胞资源,从而下调eIF2C2。 | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-氟尿嘧啶作为一种嘧啶类似物,可能会破坏核苷酸代谢。这种破坏会通过阻碍RNA合成间接影响RNAi组件,导致eIF2C2水平下降。 | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
硼替佐米抑制蛋白酶体,影响蛋白质的更新。这可能会破坏细胞蛋白质的平衡,从而降低eIF2C2的稳定性或合成。 | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
放线菌素D通过插入DNA来阻碍RNA合成。这会导致RNA相关过程的普遍下调,其中可能包括eIF2C2水平的下降。 | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
环己酰胺通过抑制蛋白质合成,可能会阻止新的eIF2C2分子的产生,导致eIF2C2的净减少,因为现有蛋白质会降解。 |